FIELD: medicine.
SUBSTANCE: invention relates to medicine, in particular to oncology and molecular biology. A minimally invasive method for diagnosing metastatic lesions of regional lymph nodes in patients with cervical cancer based on the copy number of the CCND1 and PPARGC1A genes is proposed. The relative copy number of genes (rC) is calculated using the formula rC=2-ΔC. With values of rCCCND1>(2,5±0,19)*10-3 and rCPPARGC1A<(4,1±0,02)*10-3, metastatic lesions of regional lymph nodes are diagnosed. At values rCCCND1<(0,5±0,01)*10-3 and rCPPARGC1A>(6,9±0,72)*10-3, the absence of metastatic lesions of regional lymph nodes is diagnosed.
EFFECT: invention provides creation of a new, simple, inexpensive and accurate method with unique highly specific primer sequences for minimally invasive diagnostics of metastatic lesions of regional lymph nodes in patients with cervical cancer.
4 cl, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MINIMALLY INVASIVE METHOD FOR DETECTING SENSITIVITY OF RECTAL TUMOUR TO RADIATION THERAPY BASED ON CHANGE IN ABUNDANCE OF N2AX AND RBBP8 GENES | 2019 |
|
RU2740576C1 |
| MINIMALLY INVASIVE METHOD FOR DIFFERENTIAL EARLY DIAGNOSIS OF HEPATOCELLULAR CARCINOMA AND FATTY HEPATOSIS | 2023 |
|
RU2822224C1 |
| MINIMALLY INVASIVE METHOD FOR DIAGNOSTICS OF LUNG CANCER ON BASIS OF CHANGING COPY NUMBER OF MTDNA HV2 LOCUS | 2018 |
|
RU2678227C1 |
| MINIMALLY INVASIVE METHOD FOR DIAGNOSIS OF HIGH-GRADE SEROUS OVARIAN ADENOCARCINOMA BASED ON COPY INDEX OF SULT1E1, CYP1B1, AND ESR1 GENES | 2021 |
|
RU2750472C1 |
| MINIMALLY INVASIVE METHOD FOR DETECTING SENSITIVITY OF PROSTATE TUMOURS TO RADIATION THERAPY BASED ON CHANGE IN BRCA2 AND RAD50 GENE COPYING | 2019 |
|
RU2728428C1 |
| METHOD FOR PREDICTING THE DEVELOPMENT OF METASTASES IN REGIONAL LYMPH NODES IN PATIENTS WITH GASTRIC ADENOCARCINOMA | 2017 |
|
RU2661600C1 |
| METHOD FOR PREDICTING DEVELOPMENT OF METASTASES IN PATIENTS WITH BREAST CANCER | 2018 |
|
RU2675236C1 |
| TEST-SYSTEM FOR PREDICTION OF RELAPSE DEVELOPMENT IN PATIENTS WITH UTERINE CORPUS CANCER BASED ON EXPRESSION LEVEL OF THE ESR1 GENE | 2017 |
|
RU2661599C1 |
| METHOD FOR PREDICTION OF METASTASES DEVELOPMENT IN PATIENTS WITH GASTRIC CANCER | 2016 |
|
RU2624505C1 |
| TEST SYSTEM “HV2 mtDNA-PCR” FOR PREDICTING THE DEVELOPMENT OF METASTASES IN PATIENTS WITH GASTRIC CANCER | 2017 |
|
RU2683571C1 |
